MET and lung adenocarcinoma: For example, a 77-year-old never-smoker woman with lung adenocarcinoma was reported to be refractory to Gefitinib and responsive to Crizotinib with concurrent rare mutation of EGFR (L861Q) and increased ALK/MET/ROS1 gene copy number33.